Nanocarriers For Vaginal Drug Delivery / Zeenat Iqbal, Fahima Dilnawaz
Background: Vaginal drug delivery approach represents one of the imperative strategies for local and systemic delivery of drugs. The peculiar dense vascular networks, mucus permeability, and range of physiological characteristics of the vaginal cavity have been exploited for therapeutic benefit. Furthermore, the vaginal drug delivery has been curtailed due to the influence of different physiological factors like acidic pH, constant cervical secretion, microflora, cyclic changes during periods along with turnover of mucus of varying thickness. Objective: This review highlights advancement of nanomedicine and its prospective progress towards the clinic. Methods: Relevant literature reports and patents related to topics are retrieved and used. Result: The extensive literature search and patent revealed that nanocarriers are efficacious over conventional treatment approaches. Conclusion: Recently, nanotechnology based drug delivery approach has promised better therapeutic outcomes by providing enhanced permeation and sustained drug release activity. Different nanoplatforms based on drugs, peptides, proteins, antigens, hormones, nucleic material, and microbicides are gaining momentum for vaginal therapeutics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Recent patents on drug delivery & formulation - 13(2019), 1, Seite 3- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Iqbal, Zeenat [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (13 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL009095403 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL009095403 | ||
| 003 | DE-627 | ||
| 005 | 20231128152515.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220323s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL009095403 | ||
| 035 | |a (KFL)prod_DARH_.39CBF03E0C5036DC359E98292D211CF4C56C689B | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Iqbal, Zeenat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanocarriers For Vaginal Drug Delivery |c Zeenat Iqbal, Fahima Dilnawaz |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (13 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Vaginal drug delivery approach represents one of the imperative strategies for local and systemic delivery of drugs. The peculiar dense vascular networks, mucus permeability, and range of physiological characteristics of the vaginal cavity have been exploited for therapeutic benefit. Furthermore, the vaginal drug delivery has been curtailed due to the influence of different physiological factors like acidic pH, constant cervical secretion, microflora, cyclic changes during periods along with turnover of mucus of varying thickness. Objective: This review highlights advancement of nanomedicine and its prospective progress towards the clinic. Methods: Relevant literature reports and patents related to topics are retrieved and used. Result: The extensive literature search and patent revealed that nanocarriers are efficacious over conventional treatment approaches. Conclusion: Recently, nanotechnology based drug delivery approach has promised better therapeutic outcomes by providing enhanced permeation and sustained drug release activity. Different nanoplatforms based on drugs, peptides, proteins, antigens, hormones, nucleic material, and microbicides are gaining momentum for vaginal therapeutics | ||
| 700 | 1 | |a Dilnawaz, Fahima |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Recent patents on drug delivery & formulation |d Sharjah : Bentham Science, 2007 |g 13(2019), 1, Seite 3- |h Online-Ressource |w (DE-627)KFL000006548 |w (DE-600)2365016-3 |w (DE-576)306834529 |x 2212-4039 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2019 |g number:1 |g pages:3- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1872-2113&volume=13&issue=1&spage=3 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_DARH_01 | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2019 |e 1 |h 3- | ||